Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium

被引：0
|
作者：
Jabbour, Elias [1 ]
Sasaki, Koji [1 ]
Sekeres, Mikkael A. [2 ]
Komrokji, Rami S. [3 ]
Steensma, David P. [4 ]
DeZern, Amy E. [5 ]
Gail, Roboz J. [6 ]
Daver, Naval G. [1 ]
Pemmaraju, Naveen [1 ]
Kadia, Tapan [1 ]
DiNardo, Courtney D. [1 ]
Wang, Xuemei [1 ]
Nogueras-Gonzalez, Graciela [1 ]
Borthakur, Gautam [1 ]
Estrov, Zeev [1 ]
Kantarjian, Hagop M. [1 ]
Garcia-Manero, Guillermo [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Weill Cornell Phys, New York, NY USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Outcomes of Myelodysplastic Syndromes (MDS) Patients with Chromosome 17 Abnormalities: A Report on Behalf of the MDS Clinical Research Consortium (MDSCRC)
    Komrokji, Rami S.
    Al Ali, Najla
    Barnard, John
    Steensma, David P.
    DeZern, Amy E.
    Roboz, Gail J.
    Sallman, David A.
    Padron, Eric
    Nazha, Aziz
    List, Alan F.
    Garcia-Manero, Guillermo
    Sekeres, Mikkael A.
    BLOOD, 2017, 130
  • [2] Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)
    DeZern, Amy E.
    Zeidan, Amer M.
    Barnard, John
    Hand, Wesley
    Al Ali, Najla
    Brown, Francis
    Zimmerman, Cassie
    Roboz, Gail J.
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    Steensma, David P.
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [3] Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)
    DeZern, Amy E.
    Zeidan, Amer M.
    Barnard, John
    Hand, Wesley
    Al Ali, Najla
    Brown, Francis
    Zimmerman, Cassie
    Roboz, Gail J.
    Garcia-Manero, Guillermo
    Steensma, David P.
    Komrokji, Rami S.
    Sekeres, Mikkael A.
    LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1325 - 1331
  • [4] Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs)
    Sekeres, Mikkael A.
    Zell, Katrina
    Barnard, John
    DeZern, Amy E.
    Steensma, David P.
    Zimmerman, Cassie
    Estling, Christopher
    Hand, Wesley
    Roboz, Gail J.
    Rizzo, Nicole
    Al Ali, Najla H.
    List, Alan F.
    Garcia-Manero, Guillermo
    Maciejewski, Jaroslaw P.
    Komrokji, Rami S.
    BLOOD, 2015, 126 (23)
  • [5] Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Qiao, Wei
    Strati, Paolo
    Khan, Navira F.
    Cortes, Jorge E.
    Hoehn, Daniela
    Hu, Jianhua
    Obrien, Susan
    Bryan, Jeffrey
    Prescott, Hillary
    DiNardo, Courtney D.
    Daver, Naval
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    BLOOD, 2013, 122 (21)
  • [6] Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)
    Lee, Sangmin
    Barnard, John
    DeZern, Amy E.
    Maciejewski, Jaroslaw P.
    Alali, Najla
    Steensma, David P.
    Ritchie, Ellen K.
    Desai, Pinkal
    Garcia-Manero, Guillermo
    Ali, Fatima
    Rizzo, Nicole
    Hassane, Duane C.
    Komrokji, Rami S.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    BLOOD, 2016, 128 (22)
  • [7] RISK STRATIFICATION OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (T-MDS): A REPORT ON BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM
    Komrokji, R.
    Zeidan, A.
    Al Ali, N.
    Padron, E.
    Lancet, J.
    Steensma, D.
    Dezern, A.
    Roboz, G.
    Jabbour, E.
    Sekeres, M.
    Garcia-Manero, G.
    List, A.
    LEUKEMIA RESEARCH, 2015, 39 : S158 - S159
  • [8] Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low-or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium
    Short, Nicholas J.
    Garcia-Manero, Guillermo
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Steensma, David P.
    DeZern, Amy E.
    Roboz, Gail J.
    Kadia, Tapan
    Borthakur, Gautam
    DiNardo, Courtney
    Miller, Darla
    Estrov, Zeev
    Pemmaraju, Naveen
    Daver, Naval
    Verstovsek, Srdan
    Kantarjian, Hagop M.
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [9] Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA)
    Nazha, Aziz
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Barnard, John
    Al Ali, Najla H.
    Roboz, Gail J.
    Steensma, David P.
    DeZern, Amy E.
    Zimmerman, Cassie
    Jabbour, Elias
    Greenberg, Molly D.
    Lee, Sangmin
    List, Alan F.
    Kantarjian, Hagop M.
    Maciejewski, Jaroslaw P.
    Komrokji, Rami S.
    BLOOD, 2014, 124 (21)
  • [10] Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)
    Komrokji, Rami S.
    DeZern, Amy E.
    Zell, Katrina
    Al Ali, Najla H.
    Estling, Christopher
    Zimmerman, Cassie
    Hand, Wesley
    Brown, Francis
    Rizzo, Nicole
    Barnard, John
    Roboz, Gail J.
    Garcia-Manero, Guillermo
    Steensma, David P.
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
12345